Answers are grounded in this paper and cite their sources.
Clinical investigation evaluates recombinant ADAMTS13 against standard plasma therapy in congenital thrombotic thrombocytopenic purpura, highlighting unmet treatment needs.
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived products) administered as routine prophylaxis or on-demand treatment in patients with congenital TTP is not known.
No takes yet. Share an insight, caveat, or question.
Scully et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: